Indo Cotspin manufactures and trades non-woven textile products, including carpets, felts, and fabrics, primarily serving industrial and consumer markets for flooring and technical textiles.
The company operates in a highly commoditized textile segment with no evidence of brand power or cost advantage, as evidenced by extremely low average net margins of 1.0% and a ROCE of 2.3% which is well below the cost of capital.
Management has prioritized internal reinvestment and bonus share issuances over dividends, yet the capital deployed has failed to generate meaningful returns, with ROE averaging below 2%. Recent major capital expenditure on a solar plant and building expansion has not yet translated into improved profitability.
The investment collapsed after the board executed the proposed sale of the company's core land and machinery to related parties, effectively hollowing out the operating entity for the benefit of the promoter family. While the business was already struggling with returns on capital below the cost of debt, the transition of assets to insiders left minority shareholders holding a shell company with no productive capacity. The solar and building expansions failed to offset the loss of core assets, and the remaining capital was consumed by executive compensation that remained decoupled from the company's actual earnings power.
RichFakir rates Indo Cotspin Ltd's business quality as poor — 26/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
On our model, Indo Cotspin Ltd is trading far above our estimate of fair value (expensive on our lens); we rate its price expensive. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on Indo Cotspin Ltd is: Avoid. We are steering clear of this one — the red flags below outweigh anything the price or numbers offer.
RichFakir's educational estimate of Indo Cotspin Ltd's fair value is about ₹8 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →